PMV Pharmaceuticals published Phase I results of rezatapopt — a small molecule designed to reactivate mutant p53 (TP53 Y220C) — in the New England Journal of Medicine. The first‑in‑human study across 77 heavily pretreated patients showed tolerable safety, established a recommended Phase II dose and demonstrated objective responses in tumors harboring the Y220C mutation. Biomarker data aligned with selective binding to the Y220C pocket and restoration of wild‑type p53 activity. PMV said these results support a registrational Phase II strategy and plan to pursue an NDA filing in platinum‑resistant/refractory ovarian cancer in 2027. The data provide proof‑of‑concept for mutation‑selective p53 reactivators, a long‑sought therapeutic approach, and could reframe development strategies for drugs targeting structurally defined mutant pockets.